JP2019524768A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524768A5
JP2019524768A5 JP2019505179A JP2019505179A JP2019524768A5 JP 2019524768 A5 JP2019524768 A5 JP 2019524768A5 JP 2019505179 A JP2019505179 A JP 2019505179A JP 2019505179 A JP2019505179 A JP 2019505179A JP 2019524768 A5 JP2019524768 A5 JP 2019524768A5
Authority
JP
Japan
Prior art keywords
composition
l1cam
cancer
administered
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019505179A
Other languages
English (en)
Japanese (ja)
Other versions
JP7751372B2 (ja
JP2019524768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/045145 external-priority patent/WO2018026947A1/en
Publication of JP2019524768A publication Critical patent/JP2019524768A/ja
Publication of JP2019524768A5 publication Critical patent/JP2019524768A5/ja
Priority to JP2022092913A priority Critical patent/JP2022118058A/ja
Priority to JP2025030120A priority patent/JP2025078664A/ja
Application granted granted Critical
Publication of JP7751372B2 publication Critical patent/JP7751372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019505179A 2016-08-02 2017-08-02 転移性がんの処置および転移性疾患のためのモデルシステム Active JP7751372B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022092913A JP2022118058A (ja) 2016-08-02 2022-06-08 転移性がんの処置および転移性疾患のためのモデルシステム
JP2025030120A JP2025078664A (ja) 2016-08-02 2025-02-27 転移性がんの処置および転移性疾患のためのモデルシステム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370108P 2016-08-02 2016-08-02
US62/370,108 2016-08-02
PCT/US2017/045145 WO2018026947A1 (en) 2016-08-02 2017-08-02 Treating metastatic cancer and model systems for metastatic disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022092913A Division JP2022118058A (ja) 2016-08-02 2022-06-08 転移性がんの処置および転移性疾患のためのモデルシステム
JP2025030120A Division JP2025078664A (ja) 2016-08-02 2025-02-27 転移性がんの処置および転移性疾患のためのモデルシステム

Publications (3)

Publication Number Publication Date
JP2019524768A JP2019524768A (ja) 2019-09-05
JP2019524768A5 true JP2019524768A5 (enExample) 2020-09-10
JP7751372B2 JP7751372B2 (ja) 2025-10-08

Family

ID=61073928

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019505179A Active JP7751372B2 (ja) 2016-08-02 2017-08-02 転移性がんの処置および転移性疾患のためのモデルシステム
JP2022092913A Pending JP2022118058A (ja) 2016-08-02 2022-06-08 転移性がんの処置および転移性疾患のためのモデルシステム
JP2025030120A Pending JP2025078664A (ja) 2016-08-02 2025-02-27 転移性がんの処置および転移性疾患のためのモデルシステム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022092913A Pending JP2022118058A (ja) 2016-08-02 2022-06-08 転移性がんの処置および転移性疾患のためのモデルシステム
JP2025030120A Pending JP2025078664A (ja) 2016-08-02 2025-02-27 転移性がんの処置および転移性疾患のためのモデルシステム

Country Status (9)

Country Link
US (3) US11464874B2 (enExample)
EP (2) EP4623998A3 (enExample)
JP (3) JP7751372B2 (enExample)
KR (2) KR20230170142A (enExample)
AU (2) AU2017306426B2 (enExample)
CA (1) CA3029653A1 (enExample)
ES (1) ES3037528T3 (enExample)
IL (1) IL264024A (enExample)
WO (1) WO2018026947A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
CN119930818A (zh) 2018-06-29 2025-05-06 爱必泰生物有限公司 抗l1cam抗体及其用途
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
WO2023102120A1 (en) * 2021-12-01 2023-06-08 Memorial Sloan-Kettering Cancer Center Organoid co-cultures and methods of use thereof
CN115078738A (zh) * 2022-06-30 2022-09-20 复旦大学 一种l1cam蛋白n979位点特异性核心岩藻糖基化的抑制剂的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114550A1 (en) 2006-04-03 2007-10-11 Korea Research Institute Of Bioscience And Biotechnology A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
CN101605560B (zh) * 2006-08-23 2013-06-26 韩国生命工学研究院 治疗胆管癌的药物组合物
WO2008046529A1 (en) * 2006-10-16 2008-04-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule
WO2008046459A1 (en) * 2006-10-16 2008-04-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule
CA2691075C (en) 2007-06-15 2017-04-11 Daniela Gast Treatment of tumors using specific anti-l1 antibody
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
KR20100060351A (ko) * 2008-11-27 2010-06-07 한국생명공학연구원 Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
US20130064831A1 (en) * 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
KR101271964B1 (ko) * 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
CA2924543A1 (en) * 2013-09-18 2015-03-26 Memorial Sloan-Kettering Cancer Center Inhibiting cancer metastasis
WO2015048577A2 (en) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
CN104829730A (zh) * 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用

Similar Documents

Publication Publication Date Title
Beatty et al. The biological underpinnings of therapeutic resistance in pancreatic cancer
Gao et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer
Yu et al. NEAT 1: A novel cancer‐related long non‐coding RNA
Fu et al. MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma
Iacono et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study
McIntyre et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
Wong et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2
Leblanc et al. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
Kang et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer
Sakaizawa et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
Han et al. MicroRNA-106a regulates autophagy-related cell death and EMT by targeting TP53INP1 in lung cancer with bone metastasis
Sung et al. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy
Chhabra et al. MicroRNAs in cancer stem cells: current status and future directions
CA2941769A1 (en) Determining cancer aggressiveness, prognosis and responsiveness to treatment
Eoh et al. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis
Mariani et al. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer
Lennerz et al. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma
RU2017134347A (ru) Способы лечения рака, имеющего гемизиготную потерю тр53
CN105435228A (zh) 三氧化二砷的抗肿瘤新用途及抗肿瘤制剂
Dzhugashvili et al. Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer
Zhang et al. The prognostic significance of combining VEGFA, FLT1 and KDR mRNA expressions in brain tumors
Roth et al. Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis
Kanemura et al. The tumor immune microenvironment is associated with recurrence in early-stage lung adenocarcinoma
Fuertes et al. miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication
Uzunoglu et al. CXC motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC